These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 8419023

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo.
    Freeman MR, Langer A, Wilson RF, Morgan CD, Armstrong PW.
    Circulation; 1992 Jan; 85(1):150-7. PubMed ID: 1728444
    [Abstract] [Full Text] [Related]

  • 5. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial).
    Diver DJ, Bier JD, Ferreira PE, Sharaf BL, McCabe C, Thompson B, Chaitman B, Williams DO, Braunwald E.
    Am J Cardiol; 1994 Sep 15; 74(6):531-7. PubMed ID: 8074033
    [Abstract] [Full Text] [Related]

  • 6. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction.
    Hochman JS, McCabe CH, Stone PH, Becker RC, Cannon CP, DeFeo-Fraulini T, Thompson B, Steingart R, Knatterud G, Braunwald E.
    J Am Coll Cardiol; 1997 Jul 15; 30(1):141-8. PubMed ID: 9207635
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Excimer laser in myocardial infarction: a comparison between STEMI patients with established Q-wave versus patients with non-STEMI (non-Q).
    CARMEL Excimer Laser Interventional Study Group, Topaz O, Ebersole D, Dahm JB, Alderman EL, Madyoon H, Vora K, Baker JD, Hilton D, Das T.
    Lasers Med Sci; 2008 Jan 15; 23(1):1-10. PubMed ID: 17426922
    [Abstract] [Full Text] [Related]

  • 9. Randomized, double-blind, placebo-controlled trial of tissue plasminogen activator in unstable angina.
    Nicklas JM, Topol EJ, Kander N, O'Neill WW, Walton JA, Ellis SG, Gorman L, Pitt B.
    J Am Coll Cardiol; 1989 Feb 15; 13(2):434-41. PubMed ID: 2492325
    [Abstract] [Full Text] [Related]

  • 10. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction.
    Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E.
    Am J Cardiol; 1998 Sep 15; 82(6):731-6. PubMed ID: 9761082
    [Abstract] [Full Text] [Related]

  • 11. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
    Zhao XQ, Théroux P, Snapinn SM, Sax FL.
    Circulation; 1999 Oct 12; 100(15):1609-15. PubMed ID: 10517731
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Determinants of recurrent ischaemia and revascularisation procedures after thrombolysis with recombinant tissue plasminogen activator in primary coronary occlusion.
    Wilkes NP, Jones MP, O'Rourke MF, Nelson GI.
    Int J Cardiol; 1991 Jan 12; 30(1):69-76. PubMed ID: 1899409
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correlation between clinical course and quantitative analysis of the ischemia related artery in patients with unstable angina pectoris, refractory to medical treatment. Results of two randomized trials. The European Cooperative Study Group.
    van den Brand MJ, van Miltenburg A, de Boer MJ, van der Wieken LR, de Feyter PJ, Simoons ML.
    Int J Card Imaging; 1994 Sep 12; 10(3):177-85. PubMed ID: 7876657
    [Abstract] [Full Text] [Related]

  • 19. Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group.
    Haq A, Morgan CD, Wilson RF, Daly PA, Baigrie RS, White CW, Roberts R, Gent M, Armstrong PW.
    Am J Cardiol; 1993 Aug 15; 72(5):379-83. PubMed ID: 8352178
    [Abstract] [Full Text] [Related]

  • 20. Morphological characteristics of culprit atheromatic plaque are associated with coronary flow after thrombolytic therapy: new implications of optical coherence tomography from a multicenter study.
    Toutouzas K, Tsiamis E, Karanasos A, Drakopoulou M, Synetos A, Tsioufis C, Tousoulis D, Davlouros P, Alexopoulos D, Bouki K, Apostolou T, Stefanadis C.
    JACC Cardiovasc Interv; 2010 May 15; 3(5):507-14. PubMed ID: 20488407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.